0.50
-3.21%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aprea Therapeutics
From its filings with the US Securities and Exchange Commission
Aprea Therapeutics is based in Doylestown, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker APRE. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $12.6m. At that date it held total assets of $15.9m and shareholders' equity of $12.4m.
We are a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. Our approach focuses on matching treatments to specific cancer-related genetic mutations to potentially maximize effectiveness and minimize side effects. Specifically, we develop small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. We have assembled a team with extensive experience in the discovery, development, and commercialization of oncology drugs to support our mission of developing novel synthetic lethality-based cancer therapeutics.
Aprea Therapeutics AB was originally incorporated in 2002 and commenced principal operations in 2006. On September 20, 2019, we consummated a reorganization, pursuant to which all of the issued and outstanding stock and options of Aprea Therapeutics AB were exchanged for common stock, preferred stock or options, as applicable, of Aprea Therapeutics, Inc. As a result, Aprea Therapeutics AB became a wholly-owned subsidiary of Aprea Therapeutics, Inc.
Quoted from its 10-K, filed 16 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Oct 2019
- Employees
- 8
- Website
- aprea.com ↗
- Head office
- 3805 OLD EASTON ROAD, DOYLESTOWN, PA, 18902
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Richard PetersIndependent Chairman of the Board$97,431
- Dr. Oren GiladPresident, Chief Executive Officer, Director, since 2022$760,091
- Mr. John HamillChief Financial Officer, Senior Vice President, Secretary$536,649
- Dr. Nadeem MirzaChief Medical Officer$447,738
- Mr. John HennemanLead Independent Director$75,431
- Dr. Jean-Pierre BizzariIndependent$44,000
- Mr. Marc DueyIndependent Director$62,431
- Mr. Michael GrissingerIndependent Director$71,931
- Dr. Gabriela GruiaIndependent Director$44,000
- Dr. Rifat PamukcuIndependent Director$70,431
- Dr. Bernd SeizingerIndependent Director$75,931
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 39
- Environment
- 18
- Social
- 74
- Governance
- 23
- Women in the workforce
- 50%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Boston, Massachusetts, a major biotech hub.
- Focuses on developing cancer therapeutics targeting mutant p53 tumor suppressor protein.
- Lead product candidate APR-246 is in clinical development for hematologic malignancies.
Weaknesses
- Operates with only 8 employees, indicating limited workforce capacity.
- IPO occurred in 2019, suggesting a relatively young company with limited market history.
- Relies on a single lead product candidate, APR-246, for development focus.
Opportunities
- Potential for APR-246 to address unmet needs in MDS and AML treatments.
- Development of APR-548 as an oral p53 reactivator could expand therapeutic options.
- Clinical-stage focus may attract partnerships or investment for further development.
Threats
- Dependence on a single product candidate could pose significant risk if development fails.
- Biotechnology sector is highly competitive with numerous players targeting similar therapies.
- Regulatory approval processes for cancer therapeutics are lengthy and uncertain.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.